Introduction {#section1-1479972318790269}
============

Non-cystic fibrosis (non-CF) bronchiectasis is a condition characterized by an airway inflammatory response to bacterial pathogens.^[@bibr1-1479972318790269],[@bibr2-1479972318790269]^ Patients with non-CF bronchiectasis endure sputum production, recurrent exacerbations, and progressive airway destruction.^[@bibr3-1479972318790269]^ Variable courses may lead to the disease,^[@bibr4-1479972318790269]^ and frequent exacerbations have a major influence on the quality of life.^[@bibr5-1479972318790269]^ The morbidity of bronchiectasis in the US was 1106 cases per 100,000 with an annual percentage increase of 8.74%.^[@bibr6-1479972318790269]^

Bronchiectasis management is mainly to prevent disease exacerbation and improve quality of life.^[@bibr7-1479972318790269]^ Physiotherapy,^[@bibr8-1479972318790269]^ inhalation of hyperosmolar agents,^[@bibr9-1479972318790269]^ long-term antibiotic treatment,^[@bibr10-1479972318790269]^ macrolides,^[@bibr11-1479972318790269]^ and inhaled antibiotics^[@bibr12-1479972318790269]^ are effective treatments currently.

Macrolide antibiotics have not only antibacterial but also immune-regulation effects.^[@bibr13-1479972318790269][@bibr14-1479972318790269][@bibr15-1479972318790269]--[@bibr16-1479972318790269]^ Growing evidence included high-quality randomized controlled trials (RCTs)^[@bibr2-1479972318790269],[@bibr4-1479972318790269],[@bibr11-1479972318790269]^ and systematic reviews^[@bibr10-1479972318790269],[@bibr17-1479972318790269],[@bibr18-1479972318790269]^ support the finding that azithromycin, erythromycin, and roxithromycin have a benefit in preventing exacerbations of non-CF bronchiectasis. Long-term macrolides are the only treatment agents in bronchiectasis that have been proved in randomized double-blind placebo-controlled trials to reduce exacerbations to date.^[@bibr19-1479972318790269]^

It is still uncertain which kind of macrolides will be more effective for preventing non-CF bronchiectasis from exacerbation. There are no head-to-head RCT comparisons between macrolides. This adjusted indirect treatment comparison (AITC)^[@bibr20-1479972318790269]^ is performed to evaluate the effects between macrolides.

Materials and methods {#section2-1479972318790269}
=====================

This review was registered in PROSPERO (CRD42013004656) and performed adhering to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

Literature search strategy {#section3-1479972318790269}
--------------------------

We conducted an online search up to December 2017 in PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>), Embase (<http://www.embase.com>), and the Cochrane Central Register of Controlled Trials (CENTRAL) (<http://onlinelibrary.wiley.com/cochranelibrary/>) using the expression "(erythromycin or azithromycin or clarithromycin or roxithromycin or macrolides) and bronchiectasis". In addition, we used hand-searches of the references of all identified articles and relevant review. The results were restricted to human studies.

Study eligibility {#section4-1479972318790269}
-----------------

Eligible clinical trials were defined based on the following criteria: (1) RCT, (2) patient age \>18 years, and (3) intervention with macrolides compared with placebo or another macrolide. The outcome was the rate of exacerbation or the number of patients with exacerbation.

The exclusion criteria were the following: (1) animal research, (2) case control or prospective cohort studies, and (3) reviews, letters, or case reports.

Two authors (LW and CYZ) respectively reviewed the titles and abstracts. If there were discrepancies between the reviewers, then another author (QZ), as the third investigator, was consulted to reach a consensus.

Data extraction and quality assessment {#section5-1479972318790269}
--------------------------------------

We collected data from each eligible study, including the name of the first author, publication year, study design, inclusion and exclusion criteria, cases, PubMed ID, and intervention drugs. Recommendations for reporting were followed as recommended by the PRISMA guidelines (GYH).^[@bibr21-1479972318790269],[@bibr22-1479972318790269]^ We evaluated the quality of individual records according to the Cochrane Collaboration's tool for assessing risk of bias in randomized trials,^[@bibr23-1479972318790269]^ and the details are presented in [Table 1](#table1-1479972318790269){ref-type="table"}.

###### 

Quality assessment.

![](10.1177_1479972318790269-table1)

  Author                                        Year   Design   PubMed ID   Study size   Treatment/ control   Dose                  Duration
  --------------------------------------------- ------ -------- ----------- ------------ -------------------- --------------------- ----------
  Altenburg et al.^[@bibr4-1479972318790269]^   2013   RCT      23532241    83           A/P                  250 mg once/day       52 weeks
  Cymbala et al.^[@bibr24-1479972318790269]^    2005   RCT      15813663    22           A/P                  500 mg twice/week     6 months
  Diego et al.^[@bibr25-1479972318790269]^      2013   RCT      23714268    30           A/P                  250 mg 3 times/week   3 months
  Liu et al.^[@bibr26-1479972318790269]^        2014   RCT      25580060    43           R/P                  150 mg once/day       6 months
  Serisier et al.^[@bibr2-1479972318790269]^    2013   RCT      23532242    117          E/P                  400 mg twice/day      48 weeks
  Tsang et al.^[@bibr27-1479972318790269]^      1999   RCT      10065682    21           E/P                  500 mg twice/day      8 weeks
  Wong et al.^[@bibr11-1479972318790269]^       2012   RCT      22901887    141          A/P                  500 mg 3 times/week   6 months

A: azithromycin; P: placebo; E: erythromycin; R: roxithromycin.

Statistical analysis {#section6-1479972318790269}
--------------------

An intervention meta-analysis was conducted using STATA 14.0 software (Stata Corporation, College Station, Texas, USA). Risk ratios (RR) for dichotomous variables with 95% confidence intervals (95% CI) were calculated. We measured heterogeneity using the *I* ^2^ test. Effect size within subgroups was measured using the fixed effect model if *I* ^2^ is less than 40%.

AITC was conducted between different arms using STATA and the indirect package (st0325).^[@bibr28-1479972318790269]^

Results {#section7-1479972318790269}
=======

Literature review {#section8-1479972318790269}
-----------------

Using the search strategy mentioned above, a total of 336 records were identified after duplicates had been removed. Through screening of the titles and abstracts, we retrieved 25 records for their full text, of which 7 were ultimately included in our meta-analysis. Details of exclusions are shown in [Figure 1](#fig1-1479972318790269){ref-type="fig"}. Seven studies with 457 participants were included in this meta-analysis. Risks of bias of included articles was shown in [figure 2](#fig2-1479972318790269){ref-type="fig"}.

![Study flow diagram.](10.1177_1479972318790269-fig1){#fig1-1479972318790269}

![Risk of bias.](10.1177_1479972318790269-fig2){#fig2-1479972318790269}

Direct meta-analysis of the efficacy of macrolides for non-CF bronchiectasis {#section9-1479972318790269}
----------------------------------------------------------------------------

The pooled effect shows that macrolides decreased the rate of exacerbation of non-CF bronchiectasis (RR = 0.45; 95% CI: 0.36--0.55) with heterogeneity (*I* ^2^ = 63.7%; *p* = 0.064) ([Figure 3](#fig3-1479972318790269){ref-type="fig"}), and the number of exacerbations (RR = 0.64; 95% CI: 0.54--0.76) with heterogeneity (*I* ^2^ = 55%; *p* = 0.036) ([Figure 4](#fig4-1479972318790269){ref-type="fig"}).

![The rate of exacerbation of non-CF bronchiectasis. non-CF: non-cystic fibrosis.](10.1177_1479972318790269-fig3){#fig3-1479972318790269}

![The number of exacerbations of non-CF bronchiectasis. non-CF: non-cystic fibrosis.](10.1177_1479972318790269-fig4){#fig4-1479972318790269}

Subgroup analysis showed that azithromycin and erythromycin significantly decreased the rate of exacerbation of non-CF bronchiectasis (azithromycin: RR = 0.35; 95% CI: 0.26--0.47; *p* = 0.426; *I* ^2^ = 0.0%, erythromycin: RR = 0.0.57; 95% CI: 0.42--0.77; no heterogeneity test due to inclusion of only one RCT).

Macrolides significantly reduced the number of exacerbations (azithromycin: RR = 0.52, 95% CI: 0.40--0.67; *p* = 0.421, *I* ^2^ = 0.0%; Erythromycin: RR = 0.87, 95% CI: 0.68--1.11; *p* = 0.266, *I* ^2^ = 19.2%; roxithromycin: RR = 0.66, 95% CI: 0.41--1.06; no heterogeneity test due to inclusion of only one RCT). Based on the subgroup analysis results, we speculate that the heterogeneity may come from the different interventions.

Adjusted indirect meta-analysis of the efficacy of macrolides for non-CF bronchiectasis {#section10-1479972318790269}
---------------------------------------------------------------------------------------

The network is shown in [Figure 5](#fig5-1479972318790269){ref-type="fig"}. Compared with erythromycin, azithromycin showed a significantly lower exacerbation rate (RR: 0.35, 95% CI: 0.403--0.947) ([Table 2](#table2-1479972318790269){ref-type="table"}). Compared with placebo, roxithromycin and erythromycin reduced the number of exacerbations (not statistically significant) ([Table 3](#table3-1479972318790269){ref-type="table"}), whereas azithromycin showed better results, which were significant (RR: 0.52, 95% CI: 0.4--0.67).

![The network in the adjusted indirect analysis.](10.1177_1479972318790269-fig5){#fig5-1479972318790269}

###### 

Indirect comparison exacerbation rate.

![](10.1177_1479972318790269-table2)

  Relative effect of exacerbation rate                       
  -------------------------------------- ------------------- ---------
  Azithromycin                                               
  **0.618 (0.403, 0.947)**               Erythromycin        
  0.35 (0.26, 0.47)                      0.57 (0.42, 0.77)   Placebo

Bold:Stata with indirect meta-analysis package report the result as the format of side effect(95% CI).

###### 

Indirect comparison of number of exacerbations.

![](10.1177_1479972318790269-table3)

  Relative effect of exacerbation number                                              
  ---------------------------------------- ---------------------- ------------------- ---------
  Azithromycin                                                                        
  0.826 (0.48, 1.42)                       Roxithromycin                              
  0.67 (0.286, 1.553)                      0.806 (0.314, 2.065)   Erythromycin        
  **0.52 (0.4, 0.67)**                     0.66 (0.41, 1.06)      0.87 (0.68, 1.11)   Placebo

Bold:Stata with indirect meta-analysis package report the result as the format of side effect(95% CI).

Safety evaluation {#section11-1479972318790269}
-----------------

Diarrhea, nausea, and other gastrointestinal reactions are common adverse events of macrolides. In contrast to placebo, azithromycin increased the risk of diarrhea (Pooled RR = 4.18, 95% CI: 1.7--10.28; *I* ^2^ = 0.0%, *p* = 0.002) and abnormal pain (Pooled RR = 6.11, 95% CI: 1.41--26.52; *I* ^2^ = 0.0%, *p* = 0.02) ([Table 4](#table4-1479972318790269){ref-type="table"}). However, macrolides did not show an effect of increasing nausea, rush, and headache. Additionally, cold, cough, chest pain,^[@bibr11-1479972318790269]^ QT interval prolongation,^[@bibr2-1479972318790269]^ and auditory problems^[@bibr4-1479972318790269]^ were reported. Studies reported that macrolide antibiotics may be associated with myocardial infarction^[@bibr29-1479972318790269],[@bibr30-1479972318790269]^; however, this adverse effect was not reported in the included articles.

###### 

Adverse events.

![](10.1177_1479972318790269-table4)

  Adverse events                No. of studies   RR (95% CI)            *p* Value   Heterogeneity
  ---------------- ------------ ---------------- ---------------------- ----------- -------------------------------------------
  Nausea                        4                1.29 (0.45, 3.67)      0.63        *χ* ^2^ = 5.12, *p* = 0.16, *I* ^2^ = 41%
                   A versus P   2                1.29 (0.61, 2.69)      0.5         *χ* ^2^ = 0.74, *p* = 0.39, *I* ^2^ = 0%
                   E versus P   1                0.14 (0.01, 2.66)      0.19        ---
                   R versus P   1                11.00 (0.64, 189.31)   0.1         ---
  Rash                          3                2.03 (0.75, 5.52)      0.16        *χ* ^2^ = 0.12, *p* = 0.94, *I* ^2^ = 0%
                   A versus P   1                1.86 (0.61, 5.70)      0.28        ---
                   E versus P   1                2.75 (0.12, 60.70)     0.52        ---
                   R versus P   1                3.00 (0.13, 70.42)     0.5         ---
  Diarrhea                      3                4.18 (1.70, 10.28)     0.002       *χ* ^2^ = 0.84, *p* = 0.66, *I* ^2^ = 0%
                   A versus P   3                4.18 (1.70, 10.28)     0.002       *χ* ^2^ = 0.84, *p* = 0.66, *I* ^2^ = 0%
  Abdominal pain                2                6.11 (1.41, 26.52)     0.02        *χ* ^2^ = 0.08, *p* = 0.78, *I* ^2^ = 0%
                   A versus P   2                6.11 (1.41, 26.52)     0.02        *χ* ^2^ = 0.08, *p* = 0.78, *I* ^2^ = 0%
  Headache         A versus P   2                0.69 (0.17, 2.77)      0.6         *χ* ^2^ = 0.95, *p* = 0.33, *I* ^2^ = 0%
                   A versus P   2                0.69 (0.17, 2.77)      0.6         *χ^2^ =* 0.95, *p* = 0.33, *I^2^* = 0%

A: azithromycin; P: placebo; E: erythromycin; R: roxithromycin.

Publication bias {#section12-1479972318790269}
----------------

Egger's test did not show a significant publication bias (*p* = 0.126). The funnel plot for the number of patients with bronchiectasis exacerbations appeared to be slightly asymmetrical ([Figure 6](#fig6-1479972318790269){ref-type="fig"}). However, 7 studies with 457 participants were enrolled in this meta-analysis, which may be insufficient for the assessment of publication bias.

![Publication bias of included trials.](10.1177_1479972318790269-fig6){#fig6-1479972318790269}

Discussion {#section13-1479972318790269}
==========

This AITC^[@bibr28-1479972318790269]^ suggested that based on the existing evidence, long-term treatment with macrolides significantly reduced the incidence of non-CF bronchiectasis exacerbations and that azithromycin in particular may be the most efficient intervention. Subgroup analysis showed that azithromycin and erythromycin but not roxithromycin significantly decreased the number of exacerbations of non-CF bronchiectasis. However, only one article compared the effectiveness of roxithromycin, which should be evaluated in the future.

The exact mechanism of macrolide clinical benefits in inflammatory lung diseases remains unclear.^[@bibr2-1479972318790269]^ The benefit of macrolides may not be completely due to the antibiotic effect,^[@bibr31-1479972318790269]^ as immunomodulatory effect might also played an important role.^[@bibr16-1479972318790269]^ Modulation of host responses facilitates the long-term therapeutic benefit of macrolides in cystic fibrosis and non-CF bronchiectasis.

In the same subgroup, we found little heterogeneity ([Figures 3](#fig3-1479972318790269){ref-type="fig"} and [4](#fig4-1479972318790269){ref-type="fig"}); however, heterogeneity was significant between interventions. We speculate that the heterogeneity may come from the different drugs.

The limitations of this indirect comparison meta-analysis should be mentioned. First, macrolides could cause adverse effects, especially gastrointestinal complaints; however, we did not evaluate the indirect relative adverse effects due to inadequate data from the original research. Second, all included research chose the same placebo control design. Therefore, it is suboptimal that we did not conduct the inconsistency test between direct and indirect comparisons, which may decrease the reliability of this review. Third, 7 studies with 457 participants were enrolled in this meta-analysis, which may be insufficient. The relatively small sample size limited the effectiveness of the publication bias assessment. Additional high-quality RCTs and larger sample sizes may lead to more reliable results. Multicentered, large-sample, direct head-to-head comparisons should be conducted between macrolides. Fourth, the therapeutic duration and dose were not identical, which may lead to heterogeneity.

Understandably, erythromycin is easily destroyed by acid, and the oral absorption is low. Azithromycin is stable to gastric acid. The plasma concentration of azithromycin is low, and azithromycin is mainly concentrated in lung tissue and has a longer plasma half-life than erythromycin. Concentration in lung tissue may increase the effect of azithromycin.

Studies reported that macrolide antibiotics were associated with an increased risk of myocardial infarction but not arrhythmia or cardiovascular mortality,^[@bibr30-1479972318790269]^ especially regarding erythromycin and clarithromycin. The risk of cardiovascular mortality between azithromycin and other antibiotics is not significantly different.^[@bibr29-1479972318790269]^ It seems that azithromycin is safer than erythromycin. Additional clinical trials to evaluate the safety of macrolides are needed.

Conclusion {#section14-1479972318790269}
==========

In summary, this meta-analysis suggested that long-term treatment with macrolides significantly reduced the incidence of non-CF exacerbation. Moreover, indirect treatment comparisons showed that azithromycin is more efficient than roxithromycin and erythromycin in preventing non-CF from exacerbation. Indirect evidence of adverse effects should be evaluated in the future.
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